A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HR Positive/HER-2 Negative Breast Cancer
Interventions: DRUG: NTQ1062 with Fulvestrant
Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical